PDS Biotechnology
PDSB
52 hedge funds and large institutions have $36.2M invested in PDS Biotechnology in 2022 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 19 increasing their positions, 13 reducing their positions, and 20 closing their positions.
314% more call options, than puts
Call options by funds: $2.94M | Put options by funds: $710K
46% more repeat investments, than reductions
Existing positions increased: 19 | Existing positions reduced: 13
0.23% less ownership
Funds ownership: 20.8% → 20.58% (-0.23%)
20% less funds holding
Funds holding: 65 → 52 (-13)
24% less capital invested
Capital invested by funds: $47.9M → $36.2M (-$11.7M)
65% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 20
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$1.37M |
| 2 |
Marshall Wace
London,
United Kingdom
|
+$631K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$491K |
| 4 |
Bank of America
Charlotte,
North Carolina
|
+$340K |
| 5 |
D.E. Shaw & Co
New York
|
+$332K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$997K |
| 2 |
Millennium Management
New York
|
-$743K |
| 3 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
-$609K |
| 4 |
CSS
Cubist Systematic Strategies
Stamford,
Connecticut
|
-$524K |
| 5 |
Two Sigma Investments
New York
|
-$364K |
PDSB Hedge Fund Activity: Q1 2022 in Review
52 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in PDS Biotechnology (PDSB) for Q1 2022, worth a combined $36.2M — down 24% from $47.9M a quarter earlier.
Sellers outnumbered buyers: 20 funds closed out of PDSB and 7 opened new positions — a net loss of 13 holders — while 13 trimmed existing stakes and 19 added.
The largest buyer was Renaissance Technologies, adding an estimated $1.37M. The largest seller was Susquehanna International Group, cutting an estimated $997K.
- 52 institutional investors held PDS Biotechnology (PDSB) as of Q1 2022, down from 65 in Q4 2021.
- Funds reported $36.2M of PDS Biotechnology stock for Q1 2022, down 24% quarter-over-quarter.
- 7 funds opened new PDS Biotechnology positions in Q1 2022 and 20 closed out, a net change of -13 holders.
- The largest PDS Biotechnology buyer in Q1 2022 was Renaissance Technologies, an estimated $1.37M added.
- The largest PDS Biotechnology seller in Q1 2022 was Susquehanna International Group, an estimated $997K sold.
Based on aggregated 13F filings for Q1 2022.